Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.580
-0.030 (-0.83%)
Mar 31, 2025, 12:54 PM EDT - Market open
Nanobiotix Revenue
Nanobiotix had revenue of 9.29M EUR in the half year ending June 30, 2024, with 598.95% growth. This brings the company's revenue in the last twelve months to 42.20M, up 526.17% year-over-year. In the year 2023, Nanobiotix had annual revenue of 36.21M with 658.12% growth.
Revenue (ttm)
42.20M EUR
Revenue Growth
+526.17%
P/S Ratio
3.74
Revenue / Employee
413,765 EUR
Employees
102
Market Cap
169.08M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NBTX News
- 11 hours ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 3 days ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 10 days ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 13 days ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire
- 2 months ago - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire